Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CTH | P32929 | 1/20 | 0.31 |
| ▸ | CBS | P35520 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | CPT2 | P23786 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HMGCR | P04035 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18906646 | 0.84 | ALDH1A1 (0.35) | SMN1; SMN2 | |
| SCHEMBL10301446 | 0.84 | HMGCR (0.37) | SMN1; SMN2TSHRFFAR1CPT2TDP1 | |
| SCHEMBL19392017 | 0.84 | CYP2D6 (0.31) | SMN1; SMN2TSHR | |
| SCHEMBL18490901 | 0.84 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL24813555 | 0.83 | ALDH1A1 (0.38) | SMN1; SMN2TSHRCTHCBSTHPO | |
| SCHEMBL12123157 | 0.83 | CES2 (0.31) | — | |
| SCHEMBL25855715 | 0.82 | DGAT1 (0.32) | — | |
| SCHEMBL12519879 | 0.82 | — | — | |
| SCHEMBL25522574 | 0.82 | — | — | |
| SCHEMBL25130206 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | YALE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-11173211-B2 | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210130687-A1 | LUMINESCENT CRYSTALS AND MANUFACTURING THEREOF | AVANTAMA AG (CH) | 2021-05-06 | — | — | US | disclosed |
| US-10889756-B2 | Luminescent crystals and manufacturing thereof | AVANTAMA AG (CH) | 2021-01-12 | — | — | US | disclosed |
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2020-04-30 | — | — | US | disclosed |
| US-9586985-B2 | Organic compounds as proantigens for natural killer T cells | VICTORIA LINK LIMITED (NZ) | 2017-03-07 | — | — | US | disclosed |
| US-20110098273-A1 | Oligomer-Calcium Channel Blocker Conjugates | NEKTAR THERAPEUTICS (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098273-A1 | Oligomer-Calcium Channel Blocker Conjugates | ORAI1, CACNB2, CACNA1B | SMN1; SMN2 2407/4885TSHR 3687/4885CTH 483/4885 |
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | SMN1; SMN2 2113/4885TSHR 2304/4885CTH 1639/4885 |
| US-10889756-B2 | Luminescent crystals and manufacturing thereof | C1QBP, LAS1L, C1S | SMN1; SMN2 3890/4885TSHR 4046/4885CTH 4229/4885 |
| US-11173211-B2 | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | CRBN, ARAF, VHL | SMN1; SMN2 2113/4885TSHR 2304/4885CTH 1639/4885 |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | SMN1; SMN2 2113/4885TSHR 2304/4885CTH 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.